PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29258556-9 2017 RESULTS: LPA induces MAPK family and AKT activation and pro-inflammatory transcription factors" phosphorylation (NF-kappaB, c-Jun, STAT1, and STAT3) that were inhibited by both LPAR5 and PKD family antagonists. lysophosphatidic acid 9-12 nuclear factor kappa B subunit 1 Homo sapiens 113-122 33815123-16 2021 However, JSH-23 (NF-kappaB inhibitor) pre-treatment prevented effects of LPA. lysophosphatidic acid 73-76 nuclear factor kappa B subunit 1 Homo sapiens 17-26 34982278-9 2022 Our studies further confirmed the LPA3/Gi/MAPKs/NF-kappaB signals were involved in LPA-induced oncogenic actions in ovarian cancer cells. lysophosphatidic acid 83-86 nuclear factor kappa B subunit 1 Homo sapiens 48-57 30005060-0 2018 Lysophosphatidic Acid Promotes Expression and Activation of Matrix Metalloproteinase 9 (MMP9) in THP-1 Cells via Toll-Like Receptor 4/Nuclear Factor-kappaB (TLR4/NF-kappaB) Signaling Pathway. lysophosphatidic acid 0-21 nuclear factor kappa B subunit 1 Homo sapiens 162-171 29898789-8 2018 Upon cell injury, the nuclear translocation of nuclear factor-kappa B (NF-kappaB) was promoted to facilitate the activation of downstream pro-inflammatory gene transcription, which was ameliorated by co-treatment with LPA and/or S1P. lysophosphatidic acid 218-221 nuclear factor kappa B subunit 1 Homo sapiens 47-69 29898789-8 2018 Upon cell injury, the nuclear translocation of nuclear factor-kappa B (NF-kappaB) was promoted to facilitate the activation of downstream pro-inflammatory gene transcription, which was ameliorated by co-treatment with LPA and/or S1P. lysophosphatidic acid 218-221 nuclear factor kappa B subunit 1 Homo sapiens 71-80 28765952-7 2017 Reverse transcription-quantitative polymerase chain reaction and western blot analyses additionally revealed decreased expression of SIRT1, LXRalpha and CCR7 and increased expression of NF-kappaB and its downstream factor tumor necrosis factor-alpha (TNF-alpha) in an atherogenetic condition induced by lysophosphatidic acid (LPA). lysophosphatidic acid 303-324 nuclear factor kappa B subunit 1 Homo sapiens 186-195 28765952-7 2017 Reverse transcription-quantitative polymerase chain reaction and western blot analyses additionally revealed decreased expression of SIRT1, LXRalpha and CCR7 and increased expression of NF-kappaB and its downstream factor tumor necrosis factor-alpha (TNF-alpha) in an atherogenetic condition induced by lysophosphatidic acid (LPA). lysophosphatidic acid 326-329 nuclear factor kappa B subunit 1 Homo sapiens 186-195 20068038-0 2010 Phosphorylation of Thr-516 and Ser-520 in the kinase activation loop of MEKK3 is required for lysophosphatidic acid-mediated optimal IkappaB kinase beta (IKKbeta)/nuclear factor-kappaB (NF-kappaB) activation. lysophosphatidic acid 94-115 nuclear factor kappa B subunit 1 Homo sapiens 186-195 28496416-0 2017 Lysophosphatidic Acid Is Associated with Atherosclerotic Plaque Instability by Regulating NF-kappaB Dependent Matrix Metalloproteinase-9 Expression via LPA2 in Macrophages. lysophosphatidic acid 0-21 nuclear factor kappa B subunit 1 Homo sapiens 90-99 28496416-9 2017 PDTC, NF-kappaB inhibitor, but not inhibitor of AP-1 and PPARgamma, effectively prevented LPA-induced MMP-9 expression and NF-kappaB p65 siRNA decreased MMP-9 transcription, confirming that LPA might induce MMP-9 elevation by activating NF-kappaB pathway. lysophosphatidic acid 90-93 nuclear factor kappa B subunit 1 Homo sapiens 6-15 28496416-11 2017 These findings revealed that LPA upregulated the expression of MMP-9 through activating NF-kappaB pathway in the LPA2 dependent manner, hence blocking LPA receptors signaling may provide therapeutic strategy to target plaque destabilization. lysophosphatidic acid 29-32 nuclear factor kappa B subunit 1 Homo sapiens 88-97 23747852-4 2013 Intriguingly, the angiogenic signaling mechanisms mediated by LPA have been linked to specific G-protein coupled receptors and down stream MAPK including Erk1/2, p38 and JNK, protein kinase D (PKD-1), Rho kinase (ROCK), and the NF-kappa B signaling pathways. lysophosphatidic acid 62-65 nuclear factor kappa B subunit 1 Homo sapiens 228-238 20876301-5 2010 Furthermore, through physical interactions with NF-kappaB p65, TRIP6 regulates nuclear translocation and the activation of NF-kappaB upon Fas activation or LPA stimulation. lysophosphatidic acid 156-159 nuclear factor kappa B subunit 1 Homo sapiens 48-57 20876301-5 2010 Furthermore, through physical interactions with NF-kappaB p65, TRIP6 regulates nuclear translocation and the activation of NF-kappaB upon Fas activation or LPA stimulation. lysophosphatidic acid 156-159 nuclear factor kappa B subunit 1 Homo sapiens 123-132 26151045-9 2015 LPA promoted cancer invasion through NF-kappaB, AP-1, and RhoA activities. lysophosphatidic acid 0-3 nuclear factor kappa B subunit 1 Homo sapiens 37-46 20068038-1 2010 MEKK3 serves as a critical intermediate signaling molecule in lysophosphatidic acid-mediated nuclear factor-kappaB (NF-kappaB) activation. lysophosphatidic acid 62-83 nuclear factor kappa B subunit 1 Homo sapiens 116-125 20068038-5 2010 Furthermore, substitution of these two residues with alanine abolished the ability of MEKK3 to mediate lysophosphatidic acid-induced optimal IKKbeta/NF-kappaB activation. lysophosphatidic acid 103-124 nuclear factor kappa B subunit 1 Homo sapiens 149-158 18680225-0 2008 Lysophosphatidic acid induced nuclear translocation of nuclear factor-kappaB in Panc-1 cells by mobilizing cytosolic free calcium. lysophosphatidic acid 0-21 nuclear factor kappa B subunit 1 Homo sapiens 55-76 20074357-6 2010 In contrast, LPA stimulated another prominent transcription factor NF-kappaB via the Gq-PKC pathway in an EGFR-independent manner. lysophosphatidic acid 13-16 nuclear factor kappa B subunit 1 Homo sapiens 67-76 18627789-0 2008 Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanisms. lysophosphatidic acid 0-21 nuclear factor kappa B subunit 1 Homo sapiens 146-155 18680225-1 2008 AIM: To clarify whether Lysophosphatidic acid (LPA) activates the nuclear translocation of nuclear factor-kappaB (NF-kappaB) in pancreatic cancer. lysophosphatidic acid 24-45 nuclear factor kappa B subunit 1 Homo sapiens 91-112 18680225-1 2008 AIM: To clarify whether Lysophosphatidic acid (LPA) activates the nuclear translocation of nuclear factor-kappaB (NF-kappaB) in pancreatic cancer. lysophosphatidic acid 24-45 nuclear factor kappa B subunit 1 Homo sapiens 114-123 18680225-1 2008 AIM: To clarify whether Lysophosphatidic acid (LPA) activates the nuclear translocation of nuclear factor-kappaB (NF-kappaB) in pancreatic cancer. lysophosphatidic acid 47-50 nuclear factor kappa B subunit 1 Homo sapiens 91-112 18680225-1 2008 AIM: To clarify whether Lysophosphatidic acid (LPA) activates the nuclear translocation of nuclear factor-kappaB (NF-kappaB) in pancreatic cancer. lysophosphatidic acid 47-50 nuclear factor kappa B subunit 1 Homo sapiens 114-123 18680225-11 2008 Staurosporine, a protein kinase C inhibitor, attenuated translocation of NF-kappaB induced by LPA. lysophosphatidic acid 94-97 nuclear factor kappa B subunit 1 Homo sapiens 73-82 18396013-9 2008 Knocking down expression of VEGFR1 and inhibiting activation of NFkappaB and JNK also blocked LPA induced protection against apoptosis. lysophosphatidic acid 94-97 nuclear factor kappa B subunit 1 Homo sapiens 64-72 18680225-12 2008 CONCLUSION: These findings suggest that protein kinase C is activated endogenously in Panc-1, and protein kinase C is essential for activating NF-kappaB with cytosolic calcium and that LPA induces the nuclear translocation of NF-kappaB in Panc-1 by mobilizing cytosolic free calcium. lysophosphatidic acid 185-188 nuclear factor kappa B subunit 1 Homo sapiens 226-235 18396013-7 2008 The increase in VEGF expression by LPA is mediated by the activation of c-Jun N-terminal Kinase (JNK) and transcription factor NFkappaB since blocking JNK or NFkappaB activation inhibited LPA induced VEGF expression. lysophosphatidic acid 35-38 nuclear factor kappa B subunit 1 Homo sapiens 127-135 18396013-7 2008 The increase in VEGF expression by LPA is mediated by the activation of c-Jun N-terminal Kinase (JNK) and transcription factor NFkappaB since blocking JNK or NFkappaB activation inhibited LPA induced VEGF expression. lysophosphatidic acid 35-38 nuclear factor kappa B subunit 1 Homo sapiens 158-166 18396013-7 2008 The increase in VEGF expression by LPA is mediated by the activation of c-Jun N-terminal Kinase (JNK) and transcription factor NFkappaB since blocking JNK or NFkappaB activation inhibited LPA induced VEGF expression. lysophosphatidic acid 188-191 nuclear factor kappa B subunit 1 Homo sapiens 127-135 18396013-7 2008 The increase in VEGF expression by LPA is mediated by the activation of c-Jun N-terminal Kinase (JNK) and transcription factor NFkappaB since blocking JNK or NFkappaB activation inhibited LPA induced VEGF expression. lysophosphatidic acid 188-191 nuclear factor kappa B subunit 1 Homo sapiens 158-166 16402387-0 2006 Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity. lysophosphatidic acid 0-21 nuclear factor kappa B subunit 1 Homo sapiens 108-117 17724468-2 2008 However, it is not clear what signaling components link Ras to nuclear factor (NF)-kappaB for this LPA-induced event. lysophosphatidic acid 99-102 nuclear factor kappa B subunit 1 Homo sapiens 63-89 16402387-1 2006 This study was performed to determine the relationship of lysophosphatidic acid (LPA) stimulation and increased Ras homolog A (RhoA) activity to nuclear factor kappa B (NF-kappaB) activity, and the role of these factors in regulating prostate cancer cell invasion. lysophosphatidic acid 58-79 nuclear factor kappa B subunit 1 Homo sapiens 145-167 16402387-1 2006 This study was performed to determine the relationship of lysophosphatidic acid (LPA) stimulation and increased Ras homolog A (RhoA) activity to nuclear factor kappa B (NF-kappaB) activity, and the role of these factors in regulating prostate cancer cell invasion. lysophosphatidic acid 58-79 nuclear factor kappa B subunit 1 Homo sapiens 169-178 16402387-3 2006 LPA treatment rapidly and transiently induced RhoA activity followed by maximally increased DNA binding of NF-kappaB at 1 h and AP-1 at 4 h. The LPA-induced NF-kappaB DNA binding was preceded by transient IkappaBalpha phosphorylation, and decreased total IkappaBalpha levels. lysophosphatidic acid 0-3 nuclear factor kappa B subunit 1 Homo sapiens 107-116 16402387-3 2006 LPA treatment rapidly and transiently induced RhoA activity followed by maximally increased DNA binding of NF-kappaB at 1 h and AP-1 at 4 h. The LPA-induced NF-kappaB DNA binding was preceded by transient IkappaBalpha phosphorylation, and decreased total IkappaBalpha levels. lysophosphatidic acid 0-3 nuclear factor kappa B subunit 1 Homo sapiens 157-166 16402387-3 2006 LPA treatment rapidly and transiently induced RhoA activity followed by maximally increased DNA binding of NF-kappaB at 1 h and AP-1 at 4 h. The LPA-induced NF-kappaB DNA binding was preceded by transient IkappaBalpha phosphorylation, and decreased total IkappaBalpha levels. lysophosphatidic acid 145-148 nuclear factor kappa B subunit 1 Homo sapiens 107-116 16402387-3 2006 LPA treatment rapidly and transiently induced RhoA activity followed by maximally increased DNA binding of NF-kappaB at 1 h and AP-1 at 4 h. The LPA-induced NF-kappaB DNA binding was preceded by transient IkappaBalpha phosphorylation, and decreased total IkappaBalpha levels. lysophosphatidic acid 145-148 nuclear factor kappa B subunit 1 Homo sapiens 157-166 16402387-8 2006 Each inhibitor blocked LPA-induced invasion while PDTC inhibited LPA-induced NF-kappaB and invasion to the greatest extent. lysophosphatidic acid 65-68 nuclear factor kappa B subunit 1 Homo sapiens 77-86 16402387-9 2006 These results point to a model where LPA stimulates RhoA and increased PC-3 prostate cancer cell invasion activity through an NF-kappaB-dependent pathway. lysophosphatidic acid 37-40 nuclear factor kappa B subunit 1 Homo sapiens 126-135 15471896-0 2005 Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. lysophosphatidic acid 99-120 nuclear factor kappa B subunit 1 Homo sapiens 78-87 15471896-7 2005 Pharmacological and genetic inhibition assays revealed that Gi-mediated PI3K activation phosphorylated downstream Akt and subsequently induced NF-kappaB activation causes the induction of IL-6 by LPA in SK-OV-3 cells. lysophosphatidic acid 196-199 nuclear factor kappa B subunit 1 Homo sapiens 143-152 15471896-8 2005 In summary, data presented here demonstrate that LPA is an important inducer of IL-6 and LPA-regulated IL-6 expression via a Gi/PI3K-Akt/NF-kappaB pathway in ovarian cancer cells, providing molecular therapeutic targets for treating ovarian cancer. lysophosphatidic acid 49-52 nuclear factor kappa B subunit 1 Homo sapiens 137-146 15471896-8 2005 In summary, data presented here demonstrate that LPA is an important inducer of IL-6 and LPA-regulated IL-6 expression via a Gi/PI3K-Akt/NF-kappaB pathway in ovarian cancer cells, providing molecular therapeutic targets for treating ovarian cancer. lysophosphatidic acid 89-92 nuclear factor kappa B subunit 1 Homo sapiens 137-146 15280372-0 2004 Protein kinase Cdelta mediates lysophosphatidic acid-induced NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. lysophosphatidic acid 31-52 nuclear factor kappa B subunit 1 Homo sapiens 61-70 15280372-5 2004 Here, we report that protein kinase Cdelta (PKCdelta) mediates LPA-induced NF-kappaB transcription and interleukin-8 (IL-8) secretion in HBEpCs. lysophosphatidic acid 63-66 nuclear factor kappa B subunit 1 Homo sapiens 75-84 15280372-7 2004 LPA caused a marked activation of NF-kappaB in HBEpCs as determined by IkappaB phosphorylation and of NF-kappaB nuclear translocation and a strong induction of NF-kappaB promoter-mediated luciferase activity. lysophosphatidic acid 0-3 nuclear factor kappa B subunit 1 Homo sapiens 34-43 15280372-7 2004 LPA caused a marked activation of NF-kappaB in HBEpCs as determined by IkappaB phosphorylation and of NF-kappaB nuclear translocation and a strong induction of NF-kappaB promoter-mediated luciferase activity. lysophosphatidic acid 0-3 nuclear factor kappa B subunit 1 Homo sapiens 102-111 15280372-7 2004 LPA caused a marked activation of NF-kappaB in HBEpCs as determined by IkappaB phosphorylation and of NF-kappaB nuclear translocation and a strong induction of NF-kappaB promoter-mediated luciferase activity. lysophosphatidic acid 0-3 nuclear factor kappa B subunit 1 Homo sapiens 102-111 15280372-8 2004 Furthermore, LPA-activated PKCdelta and the LPA-mediated activation of NF-kappaB and IL-8 production were attenuated by overexpression of dominant-negative PKCdelta and rottlerin. lysophosphatidic acid 13-16 nuclear factor kappa B subunit 1 Homo sapiens 71-80 15280372-10 2004 These results demonstrate for the first time that LPA is a potent stimulator of IL-8 production in HBEpCs, which involves PKCdelta/NF-kappaB signaling pathways. lysophosphatidic acid 50-53 nuclear factor kappa B subunit 1 Homo sapiens 131-140 10595650-0 1999 Lysophosphatidic acid activates nuclear factor kappa B and induces proinflammatory gene expression in endothelial cells. lysophosphatidic acid 0-21 nuclear factor kappa B subunit 1 Homo sapiens 32-54 12759391-4 2003 Cyclin D1 promoter activity was measured in LPA-treated OVCAR-3 cells cotransfected with cyclin D1 promoter-driven luciferase constructs and cDNA expression plasmids for IkappaBalphaM (a nuclear factor kappaB [NFkappaB] super-repressor). lysophosphatidic acid 44-47 nuclear factor kappa B subunit 1 Homo sapiens 210-218 10595650-3 1999 Here, we demonstrate activation of the transcription factor nuclear factor kappa B (NF-kappaB) in EC following exposure to LPA. lysophosphatidic acid 123-126 nuclear factor kappa B subunit 1 Homo sapiens 60-82 10595650-3 1999 Here, we demonstrate activation of the transcription factor nuclear factor kappa B (NF-kappaB) in EC following exposure to LPA. lysophosphatidic acid 123-126 nuclear factor kappa B subunit 1 Homo sapiens 84-93 10595650-7 1999 LPA induces a proinflammatory activation of endothelial cells that (i) involves Gi proteins; (ii) depends on phospholipase A2 activity; (iii) is associated with the activation of NF-kappaB and (iv) results in increased expression of proinflammatory genes. lysophosphatidic acid 0-3 nuclear factor kappa B subunit 1 Homo sapiens 179-188 9920937-0 1999 Lysophosphatidic acid activates NF-kappaB in fibroblasts. lysophosphatidic acid 0-21 nuclear factor kappa B subunit 1 Homo sapiens 32-41 9920937-3 1999 In the present study, we investigated the possibility that LPA activates the transcription factor NF-kappaB. lysophosphatidic acid 59-62 nuclear factor kappa B subunit 1 Homo sapiens 98-107 9920937-5 1999 We find that LPA causes a marked activation of NF-kappaB in Swiss 3T3 fibroblasts as determined by the degradation of IkappaB-alpha in the cytosol and the emergence of kappaB binding activity in nuclear extracts. lysophosphatidic acid 13-16 nuclear factor kappa B subunit 1 Homo sapiens 47-56 9920937-11 1999 The data demonstrate the utilization of multiple pathways in the activation of NF-kappaB by LPA, not inconsistent with the relevance of several families of GTP-binding regulatory proteins. lysophosphatidic acid 92-95 nuclear factor kappa B subunit 1 Homo sapiens 79-88